379 related articles for article (PubMed ID: 24021498)
21. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
[TBL] [Abstract][Full Text] [Related]
23. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
[TBL] [Abstract][Full Text] [Related]
25. Interventional Study to Evaluate the Clinical Effects and Safety of the Nutraceutical Compound BrainUp-10® in a Cohort of Patients with Alzheimer's Disease: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial.
Guzman-Martinez L; Farías GA; Tapia JP; Sánchez MP; Fuentes P; Gloger S; Maccioni RB
J Alzheimers Dis; 2021; 81(3):1231-1241. PubMed ID: 33935080
[TBL] [Abstract][Full Text] [Related]
26. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial.
Puymirat J; Bouchard JP; Mathieu J
Clin Ther; 2012 May; 34(5):1103-11. PubMed ID: 22578232
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
29. Methylphenidate for apathy and functional status in dementia of the Alzheimer type.
Padala PR; Burke WJ; Shostrom VK; Bhatia SC; Wengel SP; Potter JF; Petty F
Am J Geriatr Psychiatry; 2010 Apr; 18(4):371-4. PubMed ID: 20220576
[TBL] [Abstract][Full Text] [Related]
30. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
Schwam EM; Nicholas T; Chew R; Billing CB; Davidson W; Ambrose D; Altstiel LD
Curr Alzheimer Res; 2014; 11(5):413-21. PubMed ID: 24801218
[TBL] [Abstract][Full Text] [Related]
31. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
32. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
[TBL] [Abstract][Full Text] [Related]
33. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
34. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Lanctôt KL; Chen C; Mah E; Kiss A; Li A; Shade D; Scherer RW; Vieira D; Coulibaly H; Rosenberg PB; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer J; Herrmann N
Int Psychogeriatr; 2023 Nov; 35(11):664-672. PubMed ID: 37066690
[TBL] [Abstract][Full Text] [Related]
35. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease.
Padala PR; Padala KP; Samant RS; James GA
Int Psychogeriatr; 2020 Apr; 32(4):539-540. PubMed ID: 32019622
[No Abstract] [Full Text] [Related]
36. Efficacy of Transcranial Direct Current Stimulation Combined with Cognitive Training in the Treatment of Apathy in Patients with Alzheimer's Disease: Study Protocol for a Randomized Trial.
Nguyen JP; Boutoleau-Bretonniere C; Lefaucheur JP; Suarez A; Gaillard H; Chapelet G; Abad S; Van Langhenhove A; Nizard J; de Decker L
Rev Recent Clin Trials; 2018; 13(4):319-327. PubMed ID: 29658441
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.
Koh SH; Kwon HS; Choi SH; Jeong JH; Na HR; Lee CN; Yang Y; Lee AY; Lee JH; Park KW; Han HJ; Kim BC; Park JS; Lee JY; Kim S; Lee KY
Alzheimers Res Ther; 2021 Mar; 13(1):66. PubMed ID: 33771205
[TBL] [Abstract][Full Text] [Related]
38. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
39. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
Biederman J; Quinn D; Weiss M; Markabi S; Weidenman M; Edson K; Karlsson G; Pohlmann H; Wigal S
Paediatr Drugs; 2003; 5(12):833-41. PubMed ID: 14658924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
